vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Wingstop Inc. (WING). Click either name above to swap in a different company.
Wingstop Inc. is the larger business by last-quarter revenue ($183.7M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 7.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 8.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Wingstop Inc. is an American international fast food chain that primarily sells buffalo wings. Wingstop locations are decorated with a 1930s and 1940s pre-jet aviation theme.
ESPR vs WING — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $183.7M |
| Net Profit | — | $29.9M |
| Gross Margin | — | 86.5% |
| Operating Margin | 50.6% | 27.4% |
| Net Margin | — | 16.3% |
| Revenue YoY | 143.7% | 7.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $1.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $183.7M | ||
| Q4 25 | $168.4M | $175.7M | ||
| Q3 25 | $87.3M | $175.7M | ||
| Q2 25 | $82.4M | $174.3M | ||
| Q1 25 | $65.0M | $171.1M | ||
| Q4 24 | $69.1M | $161.8M | ||
| Q3 24 | $51.6M | $162.5M | ||
| Q2 24 | $73.8M | $155.7M |
| Q1 26 | — | $29.9M | ||
| Q4 25 | — | $26.8M | ||
| Q3 25 | $-31.3M | $28.5M | ||
| Q2 25 | $-12.7M | $26.8M | ||
| Q1 25 | $-40.5M | $92.3M | ||
| Q4 24 | — | $26.8M | ||
| Q3 24 | $-29.5M | $25.7M | ||
| Q2 24 | $-61.9M | $27.5M |
| Q1 26 | — | 86.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 85.6% | ||
| Q3 24 | — | 85.0% | ||
| Q2 24 | — | 85.4% |
| Q1 26 | — | 27.4% | ||
| Q4 25 | 50.6% | 26.7% | ||
| Q3 25 | -11.4% | 27.9% | ||
| Q2 25 | 8.6% | 25.9% | ||
| Q1 25 | -34.0% | 22.4% | ||
| Q4 24 | -6.4% | 25.9% | ||
| Q3 24 | -31.0% | 24.5% | ||
| Q2 24 | 3.5% | 26.5% |
| Q1 26 | — | 16.3% | ||
| Q4 25 | — | 15.2% | ||
| Q3 25 | -35.9% | 16.2% | ||
| Q2 25 | -15.4% | 15.4% | ||
| Q1 25 | -62.2% | 53.9% | ||
| Q4 24 | — | 16.5% | ||
| Q3 24 | -57.2% | 15.8% | ||
| Q2 24 | -83.9% | 17.7% |
| Q1 26 | — | $1.08 | ||
| Q4 25 | $0.32 | $0.99 | ||
| Q3 25 | $-0.16 | $1.02 | ||
| Q2 25 | $-0.06 | $0.96 | ||
| Q1 25 | $-0.21 | $3.24 | ||
| Q4 24 | $-0.14 | $0.91 | ||
| Q3 24 | $-0.15 | $0.88 | ||
| Q2 24 | $-0.33 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $128.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | — |
| Total Assets | $465.9M | $648.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $128.8M | ||
| Q4 25 | $167.9M | $196.6M | ||
| Q3 25 | $92.4M | $237.6M | ||
| Q2 25 | $86.1M | $227.9M | ||
| Q1 25 | $114.6M | $251.4M | ||
| Q4 24 | $144.8M | $315.9M | ||
| Q3 24 | $144.7M | $84.0M | ||
| Q2 24 | $189.3M | $96.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $-302.0M | $-736.8M | ||
| Q3 25 | $-451.4M | $-702.6M | ||
| Q2 25 | $-433.5M | $-686.0M | ||
| Q1 25 | $-426.2M | $-715.0M | ||
| Q4 24 | $-388.7M | $-675.6M | ||
| Q3 24 | $-370.2M | $-447.5M | ||
| Q2 24 | $-344.2M | $-437.5M |
| Q1 26 | — | $648.9M | ||
| Q4 25 | $465.9M | $693.4M | ||
| Q3 25 | $364.0M | $721.0M | ||
| Q2 25 | $347.1M | $708.3M | ||
| Q1 25 | $324.0M | $696.8M | ||
| Q4 24 | $343.8M | $716.2M | ||
| Q3 24 | $314.1M | $484.8M | ||
| Q2 24 | $352.3M | $451.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $57.3M | ||
| Q3 25 | $-4.3M | $63.9M | ||
| Q2 25 | $-31.4M | $6.6M | ||
| Q1 25 | $-22.6M | $25.3M | ||
| Q4 24 | $-35.0M | $7.7M | ||
| Q3 24 | $-35.3M | $69.0M | ||
| Q2 24 | $-7.2M | $36.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $34.5M | ||
| Q3 25 | — | $61.7M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | $17.3M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | $-35.5M | $54.9M | ||
| Q2 24 | $-7.3M | $25.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.6% | ||
| Q3 25 | — | 35.1% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | -68.7% | 33.8% | ||
| Q2 24 | -9.9% | 16.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 13.0% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 8.2% | ||
| Q1 25 | 0.0% | 4.7% | ||
| Q4 24 | 0.0% | 10.1% | ||
| Q3 24 | 0.3% | 8.7% | ||
| Q2 24 | 0.1% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.14× | ||
| Q3 25 | — | 2.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 2.68× | ||
| Q2 24 | — | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
WING
| Royalty revenue, franchise fees and other | $87.5M | 48% |
| Advertising fees | $63.3M | 34% |
| Company-owned restaurant sales | $33.0M | 18% |
